神经型一氧化氮合酶在肾透明细胞癌中的表达及判断临床预后的价值  

Expression of nNOS and correlation with clinical prognosis in renal clear cell carcinoma

作　　者：肖文[1] 袁长斐 熊之勇 包林[1] 楼宁[1] 阮海龙 童军伟 肖海兵[1] 谌科[1] 章小平[1] 

机构地区：[1]华中科技大学同济医学院附属协和医院泌尿外科,武汉430022

出　　处：《中华泌尿外科杂志》2017年第7期523-526,共4页Chinese Journal of Urology

基　　金：基金项目：国家自然科学基金（81372760,81672528）

摘　　要：目的探讨神经型一氧化氮合酶（neural－nitric oxide synthase，nNOS）在肾透明细胞癌中的表达情况以及判断临床预后的价值。 方法采用t检验分析癌症基因组图谱（The Cancer Genome Atlas，TCGA）数据库中1998年1月至2013年12月总体533例肾透明细胞癌样本及72例配对样本的癌和癌旁组织中nNOS mRNA表达水平的差异。Kapla－Meier法分析533例患者nNOS表达水平和临床预后的关系。蛋白质印迹法检测我院2015年3—12月收治的10例肾透明细胞癌患者术后病理标本中癌和癌旁组织中nNOS蛋白的表达差异。 结果总体533例肾透明细胞癌样本的癌和癌旁组织中nNOS mRNA的表达水平分别为2.99±0.28和－1.76±0.05，差异有统计学意义（P〈0.01）。72例配对肾透明细胞癌和癌旁组织中nNOS mRNA的表达水平分别为2.99±0.28和－1.57±0.17，差异有统计学意义（P〈0.01）。总体533例样本中临床分期T1、T2、T3、T4期的nNOS表达水平分别为－1.59±0.08、－1.96±0.13、－1.90±0.09、－2.38±0.28，差异有统计学意义（P＝0.0029）；无转移者和有转移者的表达水平分别为－1.63±0.06和－2.16±0.13，差异有统计学意义（P＝0.0009）；无复发者与复发者的表达水平分别为－1.57±0.08和－2.03±0.11，差异有统计学意义（P＝0.008）。生存分析结果显示总体533例样本中nNOS低表达者和高表达者的总体生存时间分别为（40.3±5.6）个月和（48.3±5.7）个月，无病生存时间分别为（43.6±2.2）个月和（37.1±2.1）个月，差异均有统计学意义（均P〈0.01）。10例肾癌标本中癌和癌旁组织的nNOS蛋白表达水平分别为1.02±0.16和0.61±0.11，差异有统计学意义（P〈0.05）。 结论nNOS在肾癌中低表达，其低表达预示着临床预后差。ObjectiveTo investigate the expression of neural-nitric oxide synthase （nNOS） in renal clear cell carcinoma and its clinical significance. MethodsThe expression of nNOS mRNA in 533 samples of TCGA database was analyzed with Student t test, and statistical analysis was performed to assess the relationship between nNOS expression and clinical prognosis with Kapla-Meier test. Western blot analysis of nNOS protein expression in 10 cases of clear cell renal cell carcinoma（ccRCC） from department of urology of Wuhan union hospital with student t test. ResultsThe mRNA levels of nNOS in 72 cases of ccRCC in tumor tissues and adjacent tissues and were 2.99±0.28 and -1.57±0.17, it is significantly lower than those in adjacent tissues （P〈0.01）. The mRNA levels of nNOS in 533 cases of ccRCC, in tumor tissues and adjacent tissues and were 2.99±0.28 and -1.76±0.05, it is significantly lower than those in adjacent tissues （P〈0.01 ）. A total of 533 sample studies showed a low correlation between nNOS expression and clinical T stage, T1 -1.59±0.08, T2 -1.96±0.13, T3 -1.90±0.09, T4 -2.38±0.28 （P=0.0029） and -1.63±0.06 and -2.16±0.13 between non-metastasis and no-metastasis （P=0.0009）, and -1.57±0.08 and -2.03±0.11 between non-recurrence and recurrence （P=0.008）. Survival analysis showed that the overall survival time were （40.3±5.6） months and （48.3±5.7） months in lower and higher nNOS expression, and disease free survival time were（37.1±2.1） months and （40.3±5.6） months in lower and higher nNOS expression, both with shorter time in low expression of nNOS （P〈0.01）. nNOS proteins were 1.02±0.16 and 0.61±0.11 in tumor tissues and adjacent tissues with significantly lower expression（P〈0.05）. ConclusionsThe mRNA and protein of nNOS are lower in ccRCC with a poor prognosis of ccRCC.

关 键 词：肾透明细胞癌 神经型一氧化氮合酶 预后 

分 类 号：R737.11[医药卫生—肿瘤]